HYPOGLYCEMIC AGENT SCREEN SERUM
General Information
HLAB/HOL Code: HYPOG
UPHSM LIS Test #: 028774
Schedule:
Testing Time: 2-8 Days
Testing Lab: Mayo Labs
UPHSM LIS Test #: 028774
Schedule:
Testing Time: 2-8 Days
Testing Lab: Mayo Labs
Specimen Info
Only 1 specimen type required, unless otherwise specified
Volume: 3.0 mL
Temperature: Frozen
Tube Type: Serum
Collection Info:
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Temperature: Frozen
Tube Type: Serum
Collection Info:
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Acceptability
REJECT DUE TO:
Gross hemolysis: OK
Gross lipemia: OK
Gross icterus: OK
Gross hemolysis: OK
Gross lipemia: OK
Gross icterus: OK
Methods
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
Clinical Utilities
Evaluation of suspected insulinoma characterized by hypoglycemia and increased serum insulin concentration
Detecting drugs that stimulate insulin secretion
Drugs detected by this procedure are:
-The first-generation sulfonylureas: chlorpropamide (Diabinese), tolazamide, and tolbutamide (Orinase)
-The second-generation sulfonylureas: glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Glibenclamide)
-The meglitinides: repaglinide (Prandin) and nateglinide (Starlix)
-The thiazolidinediones: pioglitazone (Actos) and rosiglitazone (Avandia)
This test is not intended for therapeutic drug monitoring but could be used to monitor compliance.
Detecting drugs that stimulate insulin secretion
Drugs detected by this procedure are:
-The first-generation sulfonylureas: chlorpropamide (Diabinese), tolazamide, and tolbutamide (Orinase)
-The second-generation sulfonylureas: glimepiride (Amaryl), glipizide (Glucotrol), and glyburide (Glibenclamide)
-The meglitinides: repaglinide (Prandin) and nateglinide (Starlix)
-The thiazolidinediones: pioglitazone (Actos) and rosiglitazone (Avandia)
This test is not intended for therapeutic drug monitoring but could be used to monitor compliance.
CPT Codes
80377
G0480-(if appropriate)
G0480-(if appropriate)
* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding
is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
Reference Range
Negative
Screening cutoff concentrations
Chlorpropamide: 100 ng/mL
Glimepiride: 20 ng/mL
Glipizide: 5 ng/mL
Glyburide: 5 ng/mL
Nateglinide: 5 ng/mL
Pioglitazone: 20 ng/mL
Repaglinide: 5 ng/mL
Rosiglitazone: 20 ng/mL
Tolazamide: 50 ng/mL
Tolbutamide: 20 ng/mL
Note: The report indicates a specific drug is positive if that drug is detected at a concentration greater than the cutoff. The test cutoff listed for each drug is lower than the concentration that will cause increased insulin and decreased glucose.
Screening cutoff concentrations
Chlorpropamide: 100 ng/mL
Glimepiride: 20 ng/mL
Glipizide: 5 ng/mL
Glyburide: 5 ng/mL
Nateglinide: 5 ng/mL
Pioglitazone: 20 ng/mL
Repaglinide: 5 ng/mL
Rosiglitazone: 20 ng/mL
Tolazamide: 50 ng/mL
Tolbutamide: 20 ng/mL
Note: The report indicates a specific drug is positive if that drug is detected at a concentration greater than the cutoff. The test cutoff listed for each drug is lower than the concentration that will cause increased insulin and decreased glucose.
